First Report of Eltrombopag Induced Severe Autoimmune Hemolytic Anemia in the Management of Waldenström Macroglobulinemia-associated Autoimmune Thrombocytopenia

Yingying Shen  
The First Affiliated Hospital of Zhejiang Chinese Medical University

Hangping Ge  
The First Affiliated Hospital of Zhejiang Chinese Medical University

Baodong Ye  
The First Affiliated Hospital of Chinese Medical University

Zhiyin Zheng  
The First Affiliated Hospital of Zhejiang Chinese Medical University

Keding Shao  
Zhejiang Chinese Medical University

Yuhong Zhou  
The First Affiliated Hospital of Zhejiang Chinese Medical University

Yiping Shen  
The First Affiliated Hospital of Zhejiang Chinese Medical University

Dijiong Wu (✉ wudijiong@zcmu.edu.cn)  
Zhejiang Provincial Hospital of TCM  https://orcid.org/0000-0003-2338-9365

Case report

Keywords: Waldenström Macroglobulinemia, immune thrombocytopenia, ibrutinib, hemolytic anemia, eltrombopag, rituximab

Posted Date: June 30th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-648698/v1

License: ©️ ️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) can be observed in Waldenström Macroglobulinemia (WM). The cause of AIHA should be carefully distinguished during the disease management.

**Case Presentation:** A 63-year-old female WM patient complicated with thrombocytopenia, who was admitted to our department with a complaint of abdominal pain. After first half of bortezomib/dexamethasone/rituximab (BRD) chemotherapy, her platelet level recovered, but subsequently decreased to extremely low level (around 1-2×10^9/L), and the patient suffered from platelet transfusion refractoriness. During the management of refractory thrombocytopenia, the patient developed severe hemolytic anemia, and further tests confirmed warm AIHA. FcγRIIa polymorphism test showed that the patient had FcγRIIa-131RH, which implied that the AIHA may not be WM-related. Given the effects of ibrutinib in controlling WM, ibrutinib single treatment was started, which quickly corrected the thrombocytopenia within five days, but not hemolysis. With a relatively safe platelet level, eltrombopag was stopped, and the hemolysis alleviated within three days after eltrombopag withdrawal.

**Conclusion:** This is the first report on eltrombopag-induced AIHA, and we should always keep in mind of the drug induced hemolysis even in disorders with autoimmune background.

Introduction

Waldenström Macroglobulinemia (WM) is a chronic lymphoproliferative disorder, with an indolent clinical course. Autoimmune thrombocytopenia (ITP) has been observed in approximately 3.8% of patients with WM and 10–20% of patients may complicated with autoimmune hemolytic anemia (AIHA). The occurrences of autoimmune disorders are thought to be related to a dysfunctional immune response associated with WM process.

The preferred management of ITP is corticosteroids if thrombocytopenia is the sole manifestation in WM (normal hemoglobin and without symptoms), and anti-lymphoma therapies such as chemotherapy should be initiated if the thrombocytopenia does not improve with previous treatment. Herein, we report a WM patient who rapidly developed pancytopenia (especially with severe ITP) refractory to dexamethasone (DXM) containing chemotherapy (BRD: Bortezomib, DXM and Rituximab), which progressed to very severe thrombocytopenia. During the management of thrombocytopenia with eltrombopag, severe AIHA occurred. Disease remission was finally achieved with the application of ibrutinib, which is an effective Bruton's tyrosine kinase inhibitor, and the AIHA ceased after withdrawal of eltrombopag. To the best of our knowledge, this is the first report of eltrombopag-induced AIHA, and ibrutinib is an ideal option for the autoimmune disorder in WM, and its effect in controlling WM-related ITP is inspiring.

Case Report
A 63-year-old female was admitted to our department with a complaint of abdominal pain on January 8, 2020, and blood routine test showed pancytopenia (WBC 1.8×10^9/L, Hb 82g/L and PLT 14×10^9/L). The patient recalled that, three months ago, she suffered from gingival bleeding for four days, but did not take it seriously after healing. Besides moderate anemia and subcutaneous bleeding, she also had multiple enlarged lymph nodes in retroperitoneum, hepatic portal area and pelvic cavity, as well as splenomegaly, as observed by abdominal computerized tomography (CT). Further examinations showed an extremely high ratio of CD19 positive cells (17.63%) in the peripheral blood. Hence, we screened for B cell originated disorders. Histopathology result showed 4% small lymphocytes and occasional lymphoplasmacytic cells in bone marrow aspiration, and there was an active proliferation of megakaryocytes (approximately 126/slide) with dysmaturity (only 9% were plate-producing). The immunophenotype of this abnormal population was positive for CD19, CD20, CD22, CD79b, CD200, sIgM and κ light chain, weak expression of CD25 and negative for CD103, CD10, CD5, CD11c, CD23, CD27, CD56, CD43, FMC-7, CD38, λ light chain, and CD138, which indicated an abnormal clonal mature B cell population. The next generation sequencing (NGS) indicated positive for MYD88 L265p mutation (c.794T>C). There was also a clonal IgM in serum (total IgM 7.65 g/L, immunoelectrophoresis showed positive for IgM and κ light chain). These clinical data supported the diagnosis of WM. In addition, the detection of Coombs’ (both direct anti-globulin test and indirect antiglobulin test), CD55/CD59, lactate dehydrogenase (LDH) showed negative.

Given the ITP-like manifestation in bone marrow morphology, a dexamethasone containing chemotherapy (BRD: Bortezomib 2 mg weekly×4, DXM 20 mg weekly×4 and Rituximab 375 mg/m^2 monthly) was initiated. The platelet counts increased to normal after the first two rounds of DXM, but decreased to 12×10^9/L after the third dose of DXM, and became refractory to platelet transfusion (Fig. 1). The platelet count was maintained at 1–2×10^9/L, and the patient did not respond to second round continued dose of DXM (20 mg qd for 4 days). The patient refused further chemotherapy, and accepted ITP-based treatment including methylprednisolone (12 mg qd), intravenous immunoglobulin (IVIG, 20 g qd×4), recombinant human thrombopoietin (TPO, 15,000U qd), and TPO receptor agonist (Eltrombopag 75 mg qd) subsequently, but remained unresponsive to all these treatment. Rituximab was continued during the course (500 mg qw×3) considering the primary WM disease (Fig. 2).

During the management of refractory thrombocytopenia, the patient suffered from severe hemolytic anemia (hemoglobin decreased from 104 g/L to 41 g/L), with increased serum indirect bilirubin (IBIL maximum was 119.7 µmol/L), LDH (maximum was 559U/L) and reticulocyte (maximum was 25.25%) (Fig. 3). The cold agglutinating titer is under 1:4, while the direct anti-globulin test (DAT) was positive for IgG and C3. And the Anti-nuclear antibody (ANA), Ham’s, Rous test, as well as ADAMST13 activity and Flare test (PNH) showed normal. To further distinguish whether the hemolysis originated from the primary disease (WM) or was drug-induced, we tested the polymorphism of FcγR. The results showed that the patient was FcγRIα 131H/R and FcγRIα 158F/V (Fig. 4), which indicated that the hemolysis may not have developed from the progression of WM. Eltrombopag was highly suspected as the cause of hemolysis, since it was initiated 10 days before the onset of hemolysis, but no published evidence was
available for its withdrawal regardless of its potential benefit in platelet recovery. Given the patient’s refusal of chemotherapy, we finally started ibrutinib with her informed consent after explaining the high risk of hemorrhage, accompanied by continuous eltrombopag daily and IVIG twice a week. Five days later, the platelet count increased significantly to $15 \times 10^9/L$, but hemolysis did not improve within 15 days, and even got worse. The dosage of ibrutinib was increased from 140 mg to 420 mg per day, and the platelet count continuously increased to around $25 \times 10^9/L$. With decreased risk of hemorrhage, eltrombopag was withdrawn, and the hemolysis stopped immediately (indicators improved every day). IBIL, LDH and absolute value of reticulocyte decreased to almost normal within 10 days, and the hemoglobin recovered in 50 days (Fig. 5). The patient continued the ibrutinib maintenance therapy for three months, and achieved very good partial remission (VGPR), with normal IgM, hemogram and stable disease.

Discussion

Autoimmune phenomenon is well recognized in B cell-associated disorders, which is mostly mediated by autoimmune monoclonal gammopathy, including IgM or IgG\textsuperscript{1,3,5,6}. The secondary immune thrombocytopenia in WM may be complement-mediated, and the severity of thrombocytopenia varies from mild to fatal\textsuperscript{1}. The primary therapy for ITP in WM is corticosteroids, or corticosteroids containing chemotherapy. For the refractory and relapse cases, splenectomy, vinca alkaloids, azathioprine, and high-dose intravenous gamma-globulin therapy may not work. According to the National Comprehensive Cancer Network (NCCN) guideline, the preferred regimens for WM include bendamustine/rituximab (BR), bortezomib/dexamethasone/rituximab (BRD), ibrutinib ± rituximab (I ± R), and rituximab/cyclophosphamide/dexamethasone (BCD), which can achieve > 80% efficacy\textsuperscript{7}.

In this case, the patient achieved quick platelet response in the first half of BRD therapy, but subsequently suffered from refractory platelet transfusion and severe thrombocytopenia. The refractory thrombocytopenia did not respond to high dose IVIG, recombinant human thrombopoietin (rhTPO), methylprednisolonol and azathioprine, respectively. Given the high response rate of eltrombopag for secondary immune thrombocytopenia in chronic lymphoproliferative disorders\textsuperscript{8}, TPO receptor agonist (TPO-RA) was tried, but the platelet count showed no improvement.

To the best of our knowledge, there is only one report about concomitant AIHA and ITP in WM, which was resolved by the combination treatment with rituximab and romiplostim\textsuperscript{9}. AIHA includes both warm AIHA and cold agglutinin disease (CAD), and the most common cause of hemolysis in B cell disorders is primary disease related\textsuperscript{10}, in which the malignant cells serve as antigen-presenting cells to T lymphocytes, and the generated autoreactive lymphocytes are involved. In WM, the majority of cases with AIHA are CAD, and DAT results always show positive for anti-C3 but negative for anti-IgG\textsuperscript{10}. Inconsistent with the literature, our case was positive for both anti-IgG and anti-C3, and warm AIHA was confirmed. IgG fragment C (Fcg)-mediated erythrophagocytosis has been recognized as the major pathogenic mechanism responsible for AIHA\textsuperscript{11–13}. To distinguish whether the warm AIHA in WM was disease-related
or drug-induced, the polymorphism of FcγRIIa was detected by Sanger sequencing. As reported, all the IgG-mediated warm AIHA in WM mostly showed FcγRIIa-131 homozygous (131 HH or 131RR) \(^4\), and the heterozygous 131RH in our case indicated that AIHA may not be WM clone-related, and drug induced AIHA was suspected. However, no clear drug was found after searching published literatures and from our experience. According to the patient’s preference, ibrutinib single treatment was initiated, which may be beneficial for the primary disease as well as secondary ITP and AIHA\(^ {14-16}\). As expected, the thrombocytopenia was quickly resolved, and became transfusion independent, but the AIHA did not resolve and even worsen, which further indicated that the AIHA was not WM-related. With a relatively safe platelet level, we discontinued eltrombopag, which was a potential suspicious drug that was started 10 days before hemolysis. Notably, the hemolysis stopped within three days (indicator improved every day) after eltrombopag withdrawal. Based on the clinical manifestations and consequent changes, we deduced that the AIHA was induced by eltrombopag.

In summary, this is the first report about eltrombopag-induced AIHA in the management of WM-associated ITP. Eltrombopag is widely used for primary immune thrombocytopenia (ITP), but eltrombopag-induced AIHA has not been reported. The mechanism of hemolysis in eltrombopag-induced WM is unclear, and may be associated with the specific disease background. Further investigations are needed. Physicians should consider the possibility of eltrombopag-induced AIHA if hemolysis develops, and drug withdrawal should be immediately initiated.

**Declarations**

**Authors Contribution**

Yingying Shen, Hangping Ge, Shao Keding and Dijiong Wu analyzed the data and wrote the paper. Dijiong Wu, Baodong Ye, Yiping Shen and Yuhong Zhou develop the treatment plan for the patient. Yingying Shen, Hangping Ge provided patient care and collected the clinical data. Yingying Shen and Dijiong Wu edited the manuscript. All authors approved the submitted version of the manuscript.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Consent for publication**

Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.

**Compliance with ethical standards**

**Ethics approval and consent to participate**

This study was approved by the ethical committee of the Zhejiang Provincial Hospital of TCM.
Funding

The present study was supported by Natural Science Foundation of Zhejiang Province (NO.LY21H290003, LY17H290005), Zhejiang Outstanding Young Talent Fund of Traditional Chinese Medicine (NO. 2015ZQ012) and Specialized Project for Scientific Research of Bases for TCM Clinical Research of State Administration of TCM (NO.JDZX2015109).

References

1. Owen RG, Lubenko A, Savage J, Parapia LA, Jack AS, Morgan GJ. Autoimmune thrombocytopenia in Waldenstrom's macroglobulinemia. Am J Hematol. 2001;66:116-9.
2. Jonsson V, Kierkegaard A, Salling S, Molander S, Andersen LP, Christiansen M, et al. Autoimmunity in Waldenstrom's macroglobulinaemia. Leuk Lymphoma. 1999;34:373-9.
3. Nakazaki K, Hangaishi A, Nakamura F, Hosoi M, Imai Y, Takahashi T, et al. IgG-associated immune thrombocytopenia in Waldenstrom macroglobulinemia. Int J Hematol. 2010;92:360-3.
4. Poulain S, Dervite I, Leleu X, Fernandes J, Stalnikiewicz L, Moreau AS, et al. Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenstrom's macroglobulinemia: association with FcgammaRIIa polymorphism. Leukemia. 2006;20:1179-81.
5. Gertz MA. Waldenstrom macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:209-17.
6. Fattizzo B, Barcellini W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. Front Oncol. 2019;9:1435.
7. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia. Lancet Haematol. 2020;7:e827-e37.
8. Visco C, Rodeghiero F, Romano A, Valeri F, Merli M, Quaresimini G, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019;134:1708-11.
9. Nozaki Y, Koshiishi M, Sueki Y, Kawashima I, Yamamoto T, Nakajima K, et al. [Successful treatment with rituximab and romiplostim for thrombocytopenia associated with Waldenstrom's macroglobulinemia initially presenting as Evans syndrome]. Rinsho Ketsueki. 2015;56:317-22.
10. Durani U, Go RS, Kay NE. Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review. Clin Adv Hematol Oncol. 2018;16:670-6.
11. Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2004:48-62.
12. van Royen-Kerkhof A, Sanders EA, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, et al. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice. Br J Haematol. 2005;130:130-7.
13. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177:208-20.

14. Tripathi A, Steingart R. Resolution of Waldenstrom Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib. J Oncol Pract. 2016;12:490-1.

15. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2020:JCO2000555.

16. Sato R, Jacob J, Gaballa S. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:1738-41.

Figures
Figure 1

Changes of hemogram during BRD (Bortezomib 2mg weekly×4, DXM 20mg weekly×4 and Rituximab 375mg/m² monthly) chemotherapy. The platelet counts increased to normal after first two rounds of BD, but decreased to 12×10⁹/L after the third round, and became refractory to platelet transfusion. Additional, the hemoglobin also decreased 8 days after third round of BD.
Figure 2

Changes of platelet count after multiple managements on thrombocytopenia. The response of platelet was not sufficient after second round DXM (20mg qd for 3days). With the consequence treatment including methylprednisolone, intravenous immunoglobulin (IVIG), recombinant human thrombopoietin (TPO) and TPO receptor agonist, no response was observed as well, and patient suffered from with platelet transfusion refractoriness.
Severe hemolytic anemia occurred during the management of thrombocytopenia. During the management of refractory thrombocytopenia, the patient suffered from severe hemolytic anemia (hemoglobin decreased from 104g/L to 41g/L), with high level serum indirect bilirubin (IBIL maximum to 119.7μmol/L), lactic dehydrogenase (LDH maximum to 559U/L) and increased reticulocyte (Ret maximum to 25.25%).

**Figure 3**

PCR and Sanger test for polymorphism of FcγR. Results showed that this patient is FcγRα 131H/R and FcγRα 158F/V.

**Figure 4**

PCR and Sanger test for polymorphism of FcγR. Results showed that this patient is FcγRα 131H/R and FcγRα 158F/V.
Figure 5

Changes of hemoglobin, platelet, and hemolysis indexes after Eltrombopag withdraw. Results shows that IBIL, LDH and Ret improved immediately within 3days after eltrombopag withdrawl, and decreased to almost normal within 10days, and the hemoglobin recovered in 50 days later.